MedTrace Logo

Stereotactic Radiotherapy Treatment for Treatment-Resistant Depression

NCT07274917 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2026-08-10

No results posted yet for this study

Summary

This study is an clinical trial aimed at evaluating the effectiveness and safety of stereotactic radiotherapy for treatment-resistant depression

Conditions

  • Treatment-Resistant Depression
  • Depressive Disorder

Interventions

DEVICE

ZAP-X

The individualized bilateral sgACC template will be imported into the ZAP-X treatment planning system. For left and right sgACC targets, the treatment plan will be automatically generated with the following set-up. The treatment will be carried out on two consecutive days.

Sponsors & Collaborators

  • Chinese PLA General Hospital

    collaborator OTHER

  • Capital Medical University

    lead OTHER

Principal Investigators

  • Gang Wang, Medical Doctor · Beijing Anding Hospital, Capital Medical University

  • Longsheng Pan, Medical Doctor · Chinese PLA General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-26
Primary Completion
2026-06-30
Completion
2026-06-30
FDA Device
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07274917 on ClinicalTrials.gov